{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T14:21:40Z","timestamp":1781014900463,"version":"3.54.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Defence Research & Development Organization (DRDO), Ministry of Defence, Government of India"},{"name":"Department of Science and Technology, Government of India"},{"name":"CSIR, New Delhi"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.drudis.2020.06.004","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T11:28:09Z","timestamp":1592220489000},"page":"1389-1402","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Oseltamivir analogs with potent anti-influenza virus activity"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4460-2682","authenticated-orcid":false,"given":"Sumit","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Goicoechea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonu","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Durvasula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2901-0339","authenticated-orcid":false,"given":"Prakasha","family":"Kempaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2133-8847","authenticated-orcid":false,"given":"Brijesh","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3759-1057","authenticated-orcid":false,"family":"Poonam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.drudis.2020.06.004_bib0005","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1021\/cr800449m","article-title":"Synthetic approaches to the neuraminidase inhibitors zanamivir (Relenza) and oseltamivir phosphate (Tamiflu) for the treatment of influenza","volume":"109","author":"Magano","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.drudis.2020.06.004_bib0010","doi-asserted-by":"crossref","first-page":"112147","DOI":"10.1016\/j.ejmech.2020.112147","article-title":"Discovery of novel \u2018Dual-site\u2019 binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors","volume":"191","author":"Ai","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.06.004_bib0015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1055\/s-0036-1584801","article-title":"Human influenza virus infections","volume":"37","author":"Peteranderl","year":"2016","journal-title":"Semin. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.drudis.2020.06.004_bib0020","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.drudis.2020.06.004_bib0025","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02091-17","article-title":"Pandemic paradox: early life H2N2 pandemic influenza infection enhanced susceptibility to death during the 2009 H1N1 pandemic","volume":"9","author":"Gagnon","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.drudis.2020.06.004_bib0030","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1080\/14656566.2019.1626824","article-title":"Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives","volume":"20","author":"Bassetti","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.drudis.2020.06.004_bib0035","series-title":"Influenza (Seasonal)","author":"WHO","year":"2018"},{"issue":"4","key":"10.1016\/j.drudis.2020.06.004_bib0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.tim.2014.01.010","article-title":"Bat-derived influenza-like viruses H17N10 and H18N11","volume":"22","author":"Wu","year":"2014","journal-title":"Trends Microbiol."},{"issue":"10","key":"10.1016\/j.drudis.2020.06.004_bib0045","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S1359-6446(98)01241-0","article-title":"Targeting influenza virus neuraminidase\u2014a new strategy for antiviral therapy","volume":"3","author":"Oxford","year":"1998","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.drudis.2020.06.004_bib0050","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41467-019-13974-w","article-title":"The inducible amphisome isolates viral hemagglutinin and defends against influenza A virus infection","volume":"11","author":"Omi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drudis.2020.06.004_bib0055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/bs.seda.2017.07.002","article-title":"Antiviral drugs","volume":"39","author":"Othumpangat","year":"2017","journal-title":"Side Effects Drugs Annu."},{"issue":"24","key":"10.1016\/j.drudis.2020.06.004_bib0060","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1016\/j.bmcl.2017.11.003","article-title":"Design, synthesis and biological evaluation of novel oseltamivir derivatives as potent neuraminidase inhibitors","volume":"27","author":"Wang","year":"2017","journal-title":"Bioorg. Med. Chemi. Lett."},{"issue":"2","key":"10.1016\/j.drudis.2020.06.004_bib0065","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.celrep.2018.03.045","article-title":"Genome-wide CRISPR\/Cas9 screen identifies host factors essential for influenza virus replication","volume":"23","author":"Han","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.drudis.2020.06.004_bib0070","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3389\/fimmu.2019.01097","article-title":"Identification and in vivo efficacy assessment of approved orally bioavailable human host protein-targeting drugs with broad anti-influenza A activity","volume":"10","author":"Enkirch","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.drudis.2020.06.004_bib0075","doi-asserted-by":"crossref","first-page":"e1958","DOI":"10.7717\/peerj.1958","article-title":"Exploring the chemical space of influenza neuraminidase inhibitors","volume":"4","author":"Anuwongcharoen","year":"2016","journal-title":"PeerJ"},{"issue":"6","key":"10.1016\/j.drudis.2020.06.004_bib0080","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2174\/0929867003374886","article-title":"Discovery and development of GS 4104 (oseltamivir) an orally active influenza neuraminidase inhibitor","volume":"7","author":"Lew","year":"2000","journal-title":"Curr. Med. Chem."},{"issue":"33","key":"10.1016\/j.drudis.2020.06.004_bib0085","article-title":"Influenza season 2019\u20132020","volume":"8","author":"Sotello","year":"2020","journal-title":"The Chronicles"},{"key":"10.1016\/j.drudis.2020.06.004_bib0090","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/IDR.S105473","article-title":"Drug resistance in influenza A virus: the epidemiology and management","volume":"10","author":"Hussain","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"10.1016\/j.drudis.2020.06.004_bib0095","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ejps.2017.10.027","article-title":"Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system","volume":"111","author":"Pires de Mello","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.drudis.2020.06.004_bib0100","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12929-019-0567-0","article-title":"Development of effective anti-influenza drugs: congeners and conjugates \u2013 a review","volume":"26","author":"Shie","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.drudis.2020.06.004_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2020.107241","article-title":"Structure-based virtual screening of influenza virus RNA polymerase inhibitors from natural compounds: molecular dynamics simulation and MM-GBSA calculation","volume":"85","author":"Jin","year":"2020","journal-title":"Comput. Biol. Chem."},{"issue":"6","key":"10.1016\/j.drudis.2020.06.004_bib0110","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.bbamem.2019.03.013","article-title":"Structural determinants of the interaction between influenza A virus matrix protein M1 and lipid membranes","volume":"1861","author":"H\u00f6fer","year":"2019","journal-title":"Biochim. Biophys. Acta Biomembr."},{"issue":"3","key":"10.1016\/j.drudis.2020.06.004_bib0115","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.drudis.2007.12.004","article-title":"Rational drug design in parasitology: trans-sialidase as a case study for Chagas disease","volume":"13","author":"Neres","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2020.06.004_bib0120","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.virol.2019.08.005","article-title":"A conserved histidine in Group-1 influenza subtype hemagglutinin proteins is essential for membrane fusion activity","volume":"536","author":"Trost","year":"2019","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.drudis.2020.06.004_bib0125","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.bbrc.2018.12.110","article-title":"BST2 inhibits infection of influenza A virus by promoting apoptosis of infected cells","volume":"509","author":"Yi","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.drudis.2020.06.004_bib0130","first-page":"9","article-title":"Current and future antivirals medications to treat influenza: mechanisms of action","volume":"3","author":"Ramirez","year":"2019","journal-title":"Univ. Louisville J. Respi. Infect."},{"key":"10.1016\/j.drudis.2020.06.004_bib0135","series-title":"Swarm intelligence in cell entry exclusion phenomena in viruses and plasmids: how to exploit intelligent gene vector self-scattering in therapeutic gene delivery","first-page":"325","author":"Tolmachov","year":"2019"},{"issue":"45","key":"10.1016\/j.drudis.2020.06.004_bib0140","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1016\/j.vaccine.2009.07.017","article-title":"Structural basis for oseltamivir resistance of influenza viruses","volume":"27","author":"Collins","year":"2009","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.drudis.2020.06.004_bib0145","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1039\/c3cc38801h","article-title":"The elusive crystal structure of the neuraminidase inhibitor Tamiflu (oseltamivir phosphate): molecular details of action","volume":"49","author":"Naumov","year":"2013","journal-title":"Chem. Commun."},{"key":"10.1016\/j.drudis.2020.06.004_bib0150","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/v10070339","article-title":"Thermodynamic, and structural analysis of drug resistance mutations in neuraminidase from the 2009 pandemic influenza virus","volume":"10","author":"Pokorn\u00e1","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2020.06.004_bib0155","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejmech.2017.01.039","article-title":"Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza A virus H1N1","volume":"128","author":"Neri-Baz\u00e1n","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.drudis.2020.06.004_bib0160","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s13337-018-0480-2","article-title":"Implications of protein conformations to modifying novel inhibitor Oseltamivir for 2009 H1N1 influenza A virus by simulation and docking studies","volume":"29","author":"Singh","year":"2018","journal-title":"VirusDis."},{"key":"10.1016\/j.drudis.2020.06.004_bib0165","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2018.05.005","article-title":"Innovation and trends in the development and approval of antiviral medicines: 1987\u20132017 and beyond","volume":"155","author":"Chaudhuri","year":"2018","journal-title":"Antivir. Res."},{"issue":"20","key":"10.1016\/j.drudis.2020.06.004_bib0170","doi-asserted-by":"crossref","first-page":"8657","DOI":"10.1021\/jm3008486","article-title":"Development of oseltamivir phosphonate congeners as anti-influenza agents","volume":"55","author":"Cheng","year":"2012","journal-title":"J. Med. Chem."},{"issue":"39","key":"10.1016\/j.drudis.2020.06.004_bib0175","doi-asserted-by":"crossref","first-page":"11892","DOI":"10.1021\/ja073992i","article-title":"Synthesis of Tamiflu and its phosphonate congeners possessing potent anti-influenza activity","volume":"129","author":"Shie","year":"2007","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.drudis.2020.06.004_bib0180","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jorganchem.2018.07.040","article-title":"Stepwise trimethylsilyl and trimethylgermyl substitutions at tetraborylmethane","volume":"873","author":"Baum","year":"2018","journal-title":"J. Organomet. Chem."},{"issue":"3","key":"10.1016\/j.drudis.2020.06.004_bib0185","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/acs.jcim.6b00519","article-title":"Structural isosteres of phosphate groups in the Protein Data Bank","volume":"57","author":"Zhang","year":"2017","journal-title":"J. Chem. Inf. Model."},{"issue":"60","key":"10.1016\/j.drudis.2020.06.004_bib0190","doi-asserted-by":"crossref","first-page":"9438","DOI":"10.1039\/C6CC04089F","article-title":"Phosphate bioisostere containing amphiphiles: a novel class of squaramide-based lipids","volume":"52","author":"Saha","year":"2016","journal-title":"Chem. Commun. (Camb)."},{"key":"10.1016\/j.drudis.2020.06.004_bib0195","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/363418a0","article-title":"Rational design of potent sialidase\u2013based inhibitors of influenza virus replication","volume":"363","author":"von Itzstein","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2020.06.004_bib0200","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fmicb.2019.00039","article-title":"Influenza virus neuraminidase structure and functions","volume":"10","author":"McAuley","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.drudis.2020.06.004_bib0205","series-title":"Infectious Diseases of the Fetus and Newborn (7th edn)","first-page":"2","article-title":"Current concepts of infections of the fetus and newborn infant","author":"Maldonado","year":"2011"},{"issue":"7","key":"10.1016\/j.drudis.2020.06.004_bib0210","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/jm00145a002","article-title":"A computational procedure for determining energetically favorable binding sites on biologically important macromolecules","volume":"28","author":"Goodford","year":"1985","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.drudis.2020.06.004_bib0215","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0003-9861(83)90135-2","article-title":"The interaction of substrate-related ketals with bacterial and viral neuraminidases","volume":"221","author":"Flashner","year":"1983","journal-title":"Arch. Biochem. Biophys."},{"issue":"5","key":"10.1016\/j.drudis.2020.06.004_bib0220","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1021\/jm00031a011","article-title":"Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis","volume":"37","author":"Taylor","year":"1994","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.drudis.2020.06.004_bib0225","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1021\/jm950294c","article-title":"A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs","volume":"39","author":"von Itzstein","year":"1996","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.drudis.2020.06.004_bib0230","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1021\/jm401977j","article-title":"Oseltamivir analogues bearing N-substituted guanidines as potent neuraminidase inhibitors","volume":"57","author":"Mooney","year":"2014","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.drudis.2020.06.004_bib0235","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1021\/acs.jmedchem.6b01227","article-title":"Inhibitors of influenza virus polymerase acidic (PA) endonuclease: contemporary developments and perspectives","volume":"60","author":"Ju","year":"2017","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.drudis.2020.06.004_bib0240","doi-asserted-by":"crossref","first-page":"8445","DOI":"10.1021\/jm500892k","article-title":"Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase","volume":"57","author":"Xie","year":"2014","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.drudis.2020.06.004_bib0245","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1021\/jm401492x","article-title":"Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A","volume":"57","author":"Schade","year":"2014","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.drudis.2020.06.004_bib0250","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1021\/tx9502047","article-title":"Microsomal catalysed N-hydroxylation of guanabenz and reduction of the N-hydroxylated metabolite: characterization of the two reactions and genotoxic potential of guanoxabenz","volume":"9","author":"Clement","year":"1996","journal-title":"Chem. Res. Toxicol."},{"issue":"2","key":"10.1016\/j.drudis.2020.06.004_bib0255","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.antiviral.2013.03.014","article-title":"Influenza virus resistance to neuraminidase inhibitors","volume":"98","author":"Samson","year":"2013","journal-title":"Antivir. Res."},{"issue":"14","key":"10.1016\/j.drudis.2020.06.004_bib0260","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1021\/jm980162u","article-title":"Structure\u2212activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors","volume":"41","author":"Kim","year":"1998","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.drudis.2020.06.004_bib0265","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1039\/c3ob40624e","article-title":"Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities","volume":"11","author":"Lin","year":"2013","journal-title":"Org. Biomol. Chem."},{"issue":"22","key":"10.1016\/j.drudis.2020.06.004_bib0270","doi-asserted-by":"crossref","first-page":"9976","DOI":"10.1021\/acs.jmedchem.8b01065","article-title":"Structure-based optimization of N-substituted oseltamivir derivatives as potent anti-influenza A virus agents with significantly improved potency against oseltamivir-resistant N1-H274Y variant","volume":"61","author":"Zhang","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.06.004_bib0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111635","article-title":"Novel N-substituted oseltamivir derivatives as potent influenza neuraminidase inhibitors: Design, synthesis, biological evaluation, ADME prediction and molecular docking studies","volume":"182","author":"Ye","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.06.004_bib0280","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejmech.2019.05.076","article-title":"Design, synthesis and biological evaluation of \u2018Multi-Site\u2019-binding influenza virus neuraminidase inhibitors","volume":"178","author":"Jia","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.06.004_bib0285","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/ncomms1114","article-title":"Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase","volume":"1","author":"Rudrawar","year":"2010","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.drudis.2020.06.004_bib0290","doi-asserted-by":"crossref","first-page":"7377","DOI":"10.1021\/jm100822f","article-title":"Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles","volume":"53","author":"Mohan","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.06.004_bib0295","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nrd2400","article-title":"The war against influenza: discovery and development of sialidase inhibitors","volume":"6","author":"von Itzstein","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.drudis.2020.06.004_bib0300","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1128\/AAC.37.7.1473","article-title":"4-Guanidino-2,4-dideoxy-2,3-dehydro-N\u2013acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro","volume":"37","author":"Woods","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.drudis.2020.06.004_bib0305","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1128\/AAC.42.3.647","article-title":"Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071","volume":"42","author":"Li","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6428","key":"10.1016\/j.drudis.2020.06.004_bib0310","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/363418a0","article-title":"Rational design of potent sialidase-based inhibitors of influenza virus replication","volume":"363","author":"von Itzstein","year":"1993","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.drudis.2020.06.004_bib0315","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1016\/j.bmc.2011.06.080","article-title":"Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir","volume":"19","author":"Liu","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2020.06.004_bib0320","doi-asserted-by":"crossref","unstructured":"Sajid, M.A. et al. (2017) Recent advances in thymidine phosphorylase inhibitors: syntheses and prospective medicinal applications, Turk. J. Chem. 41 (1), 1\u201328.","DOI":"10.3906\/kim-1602-79"},{"key":"10.1016\/j.drudis.2020.06.004_bib0325","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1038\/srep02871","article-title":"Structural basis for a class of nanomolar influenza A neuraminidase inhibitors","volume":"3","author":"Kerry","year":"2013","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.drudis.2020.06.004_bib0330","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/11534730-000000000-00000","article-title":"Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A\/H1N1 influenza","volume":"49","author":"Widmer","year":"2010","journal-title":"Clin. Pharmacokinet."},{"issue":"18","key":"10.1016\/j.drudis.2020.06.004_bib0335","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1021\/ol061454p","article-title":"NG-hydroxyguanidines from primary amines","volume":"8","author":"Martin","year":"2006","journal-title":"Org. Lett."},{"issue":"9","key":"10.1016\/j.drudis.2020.06.004_bib0340","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1016\/j.bmc.2011.03.039","article-title":"Inhibitor selectivity of a new class of oseltamivir analogs against viral neuraminidase over human neuraminidase enzymes","volume":"19","author":"Albohy","year":"2011","journal-title":"Bioorg. Med. Chem."},{"issue":"12","key":"10.1016\/j.drudis.2020.06.004_bib0345","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.bmcl.2018.03.056","article-title":"Discovery of a bicyclo [4.3. 0] nonane derivative DS88790512 as a potent, selective, and orally bioavailable blocker of transient receptor potential canonical 6 (TRPC6)","volume":"28","author":"Motoyama","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.drudis.2020.06.004_bib0350","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/mp300564v","article-title":"Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue","volume":"10","author":"Gupta","year":"2013","journal-title":"Mol. Pharm."},{"issue":"21","key":"10.1016\/j.drudis.2020.06.004_bib0355","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1021\/jm300931y","article-title":"Acyl guanidine inhibitors of \u03b2-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid- and solution-phase library synthesis","volume":"55","author":"Gerritz","year":"2012","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.drudis.2020.06.004_bib0360","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/0049825021000012592","article-title":"Oxidative activation of acylguanidine prodrugs: intestinal presystemic activation in rats limits absorption and can be inhibited by co-administration of ketoconazole","volume":"33","author":"Obermeier","year":"2003","journal-title":"Xenobiotica"},{"issue":"17","key":"10.1016\/j.drudis.2020.06.004_bib0365","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1016\/j.bmc.2010.07.028","article-title":"NG-Acyl-argininamides as NPY Y1 receptor antagonists: influence of structurally diverse acyl substituents on stability and affinity","volume":"18","author":"Weiss","year":"2010","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.drudis.2020.06.004_bib0370","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1016\/j.bmc.2017.03.052","article-title":"Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors","volume":"25","author":"Li","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.drudis.2020.06.004_bib0375","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejmech.2018.05.030","article-title":"Acylguanidine derivatives of zanamivir and oseltamivir: potential orally available prodrugs against influenza viruses","volume":"154","author":"Hsu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.06.004_bib0380","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/ncomms1390","article-title":"Mechanism of 150-cavity formation in influenza neuraminidase","volume":"2","author":"Amaro","year":"2011","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drudis.2020.06.004_bib0385","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ejmech.2016.07.064","article-title":") Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors","volume":"123","author":"Das","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.06.004_bib0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111841","article-title":"Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A","volume":"185","author":"Wang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.drudis.2020.06.004_bib0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111940","article-title":"Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity","volume":"187","author":"Ju","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"21","key":"10.1016\/j.drudis.2020.06.004_bib0400","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1016\/j.bmcl.2018.09.014","article-title":"Design, synthesis, and evaluation of carboxyl-modified oseltamivir derivatives with improved lipophilicity as neuraminidase inhibitors","volume":"28","author":"Wang","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.drudis.2020.06.004_bib0405","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejmech.2018.01.050","article-title":"Discovery of C-1 modified oseltamivir derivatives as potent influenza neuraminidase inhibitors","volume":"146","author":"Ju","year":"2018","journal-title":"Eur. J. Med. Chem."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644620302294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644620302294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:47:19Z","timestamp":1761223639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644620302294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":81,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1359644620302294"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2020.06.004","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oseltamivir analogs with potent anti-influenza virus activity","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2020.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}